Abnormal genetic alterations, such as epidermal growth factor receptor (EGFR) (Castellanos et al., 2016; Rodriguezcanales et al., 2016; Liu et al., 2017) and epidermal growth factor receptor 2 (HER2) (Pillai et al., 2014; Catherine et al., 2017), are frequently described to participate in the development of lung cancer. Here, EGFR is linked to lung carcinoma.